

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT8041147

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
CALITHERA BIOSCIENCES, INC.	05/15/2023
RECEIVING PARTY DATA	
Name:	FAETH THERAPEUTICS, INC.
Street Address:	701 TILLERY STREET #12
Internal Address:	#1010
City:	AUSTIN
State/Country:	TEXAS
Postal Code:	78702
PROPERTY NUMBERS Total: 20	
Property Type	Number
Application Number:	12586241
Application Number:	12586309
Application Number:	13893163
Application Number:	13893187
Application Number:	14727336
Application Number:	15092833
Application Number:	15631375
Application Number:	15856510
Application Number:	16058306
Application Number:	16286753
Application Number:	16570182
Application Number:	16849128
Application Number:	17092957
Application Number:	17326813
Application Number:	17564723
Application Number:	17884934
Application Number:	18125325
Application Number:	13683967
Application Number:	14360267

Property Type	Number
Application Number:	14884120

CORRESPONDENCE DATA

Fax Number: (202)842-7899
Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 202-842-7800

Email: zIPPatentDocketingMailboxUS@cooley.com, TTNguyen@cooley.com

Correspondent Name: COOLEY LLP: ATTN PATENT GROUP

Address Line 1: 1299 PENNSYLVANIA AVENUE NW

Address Line 2: SUITE 700

Address Line 4: WASHINGTON, D.C. 20004

ATTORNEY DOCKET NUMBER:	FATH-001/04US ET AL.
NAME OF SUBMITTER:	SCOTT K. SHAW
SIGNATURE:	/Scott K. Shaw/
DATE SIGNED:	07/05/2023

Total Attachments: 11

source=Faeth - Calithera - APA - Patent Assignment Agreement#page1.tif
source=Faeth - Calithera - APA - Patent Assignment Agreement#page2.tif
source=Faeth - Calithera - APA - Patent Assignment Agreement#page3.tif
source=Faeth - Calithera - APA - Patent Assignment Agreement#page4.tif
source=Faeth - Calithera - APA - Patent Assignment Agreement#page5.tif
source=Faeth - Calithera - APA - Patent Assignment Agreement#page6.tif
source=Faeth - Calithera - APA - Patent Assignment Agreement#page7.tif
source=Faeth - Calithera - APA - Patent Assignment Agreement#page8.tif
source=Faeth - Calithera - APA - Patent Assignment Agreement#page9.tif
source=Faeth - Calithera - APA - Patent Assignment Agreement#page10.tif
source=Faeth - Calithera - APA - Patent Assignment Agreement#page11.tif

EXHIBIT B

Patent Assignment Agreement

This PATENT ASSIGNMENT AGREEMENT (this “Patent Assignment Agreement”) effective as of May 15, 2023 (the “Effective Date”), is executed by Calithera Biosciences, Inc., a Delaware corporation (“Seller”) and delivered to Faeth Therapeutics, Inc., a Delaware corporation (“Purchaser”). All capitalized terms used and not defined herein shall have the meanings ascribed to them in that certain Asset Purchase Agreement (the “APA”), effective as of the Effective Date, by and between Seller and Purchaser.

WHEREAS, Seller is the owner of certain patents and patent applications as set forth in **Annex 1** attached hereto (the “Assigned Patents”); and

WHEREAS, pursuant to the APA, Seller has agreed to sell, assign, transfer and deliver to Purchaser all right, title and interest in and to the Assigned Patents;

NOW, THEREFORE, in consideration of the foregoing premises and of other valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

1. **Assignment of Patents**. Effective as of the Effective Date, Seller sells, transfers, conveys, assigns and delivers to Purchaser and Purchaser accepts all right, title and interest of Seller in and to (a) the patents and patent applications set forth in **Annex 1** hereto; (b) all inventions and improvements described and claimed therein, and all divisions, reissues, substitutions, continuations, continuations-in-part, reexaminations, foreign counterparts and extensions thereof claiming priority to the underlying said patent rights, and patents which may be granted from any of the foregoing; (c) all income, royalties, damages, claims, and payments now or hereafter due or payable under and with respect thereto, including, without limitation, damages, claims, and payments for past and future infringements thereof; (d) all rights to sue for past, present, and future infringements of the foregoing, including the right to settle suits involving claims and demands for royalties owing; (e) all rights corresponding to any of the foregoing throughout the world; (f) all patent term extensions or restorations by existing or future extension or restoration mechanisms, including any supplementary protection certificates and the like of the foregoing patents and patent applications; and (g) the right to assign the rights conveyed herein, the same to be held and enjoyed by Purchaser for Purchaser’s own use and benefit, and for the benefit of Purchaser’s successors, assigns, and legal representatives.

2. **Terms of APA**. The parties hereto acknowledge and agree that this Patent Assignment Agreement is entered into pursuant to the APA, to which reference is made for a further statement of the rights and obligations of Seller and Purchaser with respect to the Assigned Patents. In the event of any conflict or inconsistency between the terms of the APA and the terms of this Patent Assignment Agreement, the terms of the APA shall govern.

3. **Recordation and Further Actions**. Seller hereby authorizes the Commissioner for Patents and the Commissioner for Trademarks in the United States Patent and Trademark Office and the officials of corresponding entities or agencies in any applicable jurisdictions to record and register this Patent Assignment Agreement upon request by Purchaser. For thirty (30) days following the Effective Date, upon Purchaser’s reasonable request and at Purchaser’s expense, Seller shall take such steps and actions, and provide such cooperation and assistance to Purchaser and Purchaser’s successors, assigns and legal representatives, including the execution and delivery of any affidavits, declarations, oaths, exhibits, assignments, powers of attorney, or other documents, as may be reasonably necessary to effect, evidence or perfect the assignment of the Assigned Patents to Purchaser, or any assignee or successor thereto.

4. Successors. This Patent Assignment Agreement shall inure to the benefit of and is binding upon the respective successors and assigns of Seller and Purchaser.

5. Governing Law. This Patent Assignment Agreement (including construction, validity and performance hereof) and all disputes or controversies arising out of or relating to this Patent Assignment Agreement or the transactions contemplated hereby shall be governed by and interpreted in accordance with the internal laws of the State of Delaware as applied to contracts made between Delaware residents in Delaware and solely to be performed in Delaware (without reference to conflicts of law principles).

6. Counterparts. This Patent Assignment Agreement may be executed in one or more counterparts, each of which shall be deemed an original and all of which shall together constitute one and the same instrument. Delivery of an executed counterpart of a signature page to this Patent Assignment Agreement by facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, the Uniform Electronic Transactions Act or other applicable law, *e.g.*, www.docusign.com) or other transmission method and any counterpart so delivered shall be effective as delivery of a manually-executed counterpart thereof and shall be deemed an original signature for all purposes.

[Signature Page Follows]

IN WITNESS WHEREOF, Seller has caused this Patent Assignment Agreement to be duly executed effective as of the Effective Date.

Calithera Biosciences, Inc.

By: Stephanie Wong
Name: Stephanie Wong
Title: CFO

ACCEPTED:

Faeth Therapeutics, Inc.

By: _____
Name: Anand Parikh
Title: CEO

IN WITNESS WHEREOF, Seller has caused this Patent Assignment Agreement to be duly executed effective as of the Effective Date.

Calithera Biosciences, Inc.

By: _____
Name: Stephanie Wong
Title: CFO

ACCEPTED:

Faeth Therapeutics, Inc.

By: Anand Parikh
Name: Anand Parikh
Title: CEO

Annex 1 to Patent Assignment Agreement - Assigned Patents

Country Name	Serial Number	Patent Number	Status	Title
CBM-228 Family 2				
United States of America	12/586241	US8476431	Granted	Benzoxazole kinase inhibitors and methods of use
United States of America	12/586309	US8476282	Granted	Benzoxazole kinase inhibitors and methods of use
United States of America	13/893163		Abandoned	Benzoxazole kinase inhibitors and methods of use
United States of America	13/893187		Abandoned	Benzoxazole kinase inhibitors and methods of use
United States of America	14/727336	US9345706	Granted	Benzoxazole kinase inhibitors and methods of use
United States of America	15/092833		Abandoned	Benzoxazole kinase inhibitors and methods of use
United States of America	15/631375		Abandoned	Benzoxazole kinase inhibitors and methods of use
United States of America	15/856510		Abandoned	Benzoxazole kinase inhibitors and methods of use
United States of America	16/058306		Abandoned	Benzoxazole kinase inhibitors and methods of use
United States of America	16/286753		Abandoned	Benzoxazole kinase inhibitors and methods of use
United States of America	16/570182		Abandoned	Benzoxazole kinase inhibitors and methods of use
United States of America	16/849128		Abandoned	Benzoxazole kinase inhibitors and methods of use
United States of America	17/092957		Abandoned	Benzoxazole kinase inhibitors and methods of use
United States of America	17/326813		Abandoned	Benzoxazole kinase inhibitors and methods of use
United States of America	17/564723		Abandoned	Benzoxazole kinase inhibitors and methods of use
United States of America	17/884934		Abandoned	Benzoxazole kinase inhibitors and methods of use
United States of America	18/125325		Pending	Benzoxazole kinase inhibitors and methods of use
United States of America	61/198200		Expired	Benzoxazole kinase inhibitors and methods of use
United States of America	61/201923		Expired	Benzoxazole kinase inhibitors and methods of use
United States of America	61/214261		Expired	Benzoxazole kinase inhibitors and methods of use
United States of America	61/230655		Expired	Benzoxazole kinase inhibitors and methods of use
Patent Cooperation Treaty	PCT/US09/05958		Expired	Benzoxazole kinase inhibitors and methods of use
Patent Cooperation Treaty	PCT/US09/05959		Nationalized	Benzoxazole kinase inhibitors and methods of use
Australia	2009310364	AU2009310364	Granted	Benzoxazole kinase inhibitors and methods of use
Brazil	PI 0920500-4	BRPI0920500	Granted	Benzoxazole kinase inhibitors and methods of use
Canada	2741898	CA2741898	Granted	Benzoxazole kinase inhibitors and methods of use
China (People's Republic)	201510006838.6	CN104710428	Granted	Benzoxazole kinase inhibitors and methods of use
China (People's Republic)	200980153705.4	CN102271513	Granted	Benzoxazole kinase inhibitors and methods of use

PATENT

REEL: 064156 FRAME: 0750

Annex 1 to Patent Assignment Agreement - Assigned Patents

European Patent Convention

09823947.8

EP2365750

Granted

Benzoxazole kinase inhibitors and methods of use

<i>Austria</i>	<i>09823947.8</i>	<i>EP2365750</i>	<i>Benzoxazole kinase inhibitors and methods of use</i>
<i>Belgium</i>	<i>09823947.8</i>	<i>EP2365750</i>	<i>Benzoxazole kinase inhibitors and methods of use</i>
<i>Bulgaria</i>	<i>09823947.8</i>	<i>EP2365750</i>	<i>Benzoxazole kinase inhibitors and methods of use</i>
<i>Switzerland</i>	<i>09823947.8</i>	<i>EP2365750</i>	<i>Benzoxazole kinase inhibitors and methods of use</i>
<i>Cyprus</i>	<i>09823947.8</i>	<i>EP2365750</i>	<i>Benzoxazole kinase inhibitors and methods of use</i>
<i>Czech Republic</i>	<i>09823947.8</i>	<i>EP2365750</i>	<i>Benzoxazole kinase inhibitors and methods of use</i>
<i>Germany</i>	<i>09823947.8</i>	<i>EP2365750</i>	<i>Benzoxazole kinase inhibitors and methods of use</i>
<i>Denmark</i>	<i>09823947.8</i>	<i>EP2365750</i>	<i>Benzoxazole kinase inhibitors and methods of use</i>
<i>Estonia</i>	<i>09823947.8</i>	<i>EP2365750</i>	<i>Benzoxazole kinase inhibitors and methods of use</i>
<i>Spain</i>	<i>09823947.8</i>	<i>EP2365750</i>	<i>Benzoxazole kinase inhibitors and methods of use</i>
<i>Finland</i>	<i>09823947.8</i>	<i>EP2365750</i>	<i>Benzoxazole kinase inhibitors and methods of use</i>
<i>France</i>	<i>09823947.8</i>	<i>EP2365750</i>	<i>Benzoxazole kinase inhibitors and methods of use</i>
<i>United Kingdom</i>	<i>09823947.8</i>	<i>EP2365750</i>	<i>Benzoxazole kinase inhibitors and methods of use</i>
<i>Greece</i>	<i>09823947.8</i>	<i>EP2365750</i>	<i>Benzoxazole kinase inhibitors and methods of use</i>
<i>Croatia</i>	<i>09823947.8</i>	<i>EP2365750</i>	<i>Benzoxazole kinase inhibitors and methods of use</i>
<i>Hungary</i>	<i>09823947.8</i>	<i>EP2365750</i>	<i>Benzoxazole kinase inhibitors and methods of use</i>
<i>Ireland</i>	<i>09823947.8</i>	<i>EP2365750</i>	<i>Benzoxazole kinase inhibitors and methods of use</i>
<i>Iceland</i>	<i>09823947.8</i>	<i>EP2365750</i>	<i>Benzoxazole kinase inhibitors and methods of use</i>
<i>Italy</i>	<i>09823947.8</i>	<i>EP2365750</i>	<i>Benzoxazole kinase inhibitors and methods of use</i>
<i>Lithuania</i>	<i>09823947.8</i>	<i>EP2365750</i>	<i>Benzoxazole kinase inhibitors and methods of use</i>
<i>Luxembourg</i>	<i>09823947.8</i>	<i>EP2365750</i>	<i>Benzoxazole kinase inhibitors and methods of use</i>
<i>Latvia</i>	<i>09823947.8</i>	<i>EP2365750</i>	<i>Benzoxazole kinase inhibitors and methods of use</i>
<i>Monaco</i>	<i>09823947.8</i>	<i>EP2365750</i>	<i>Benzoxazole kinase inhibitors and methods of use</i>
<i>Macedonia</i>	<i>09823947.8</i>	<i>EP2365750</i>	<i>Benzoxazole kinase inhibitors and methods of use</i>
<i>Malta</i>	<i>09823947.8</i>	<i>EP2365750</i>	<i>Benzoxazole kinase inhibitors and methods of use</i>
<i>Netherlands</i>	<i>09823947.8</i>	<i>EP2365750</i>	<i>Benzoxazole kinase inhibitors and methods of use</i>
<i>Norway</i>	<i>09823947.8</i>	<i>EP2365750</i>	<i>Benzoxazole kinase inhibitors and methods of use</i>
<i>Poland</i>	<i>09823947.8</i>	<i>EP2365750</i>	<i>Benzoxazole kinase inhibitors and methods of use</i>
<i>Portugal</i>	<i>09823947.8</i>	<i>EP2365750</i>	<i>Benzoxazole kinase inhibitors and methods of use</i>
<i>Romania</i>	<i>09823947.8</i>	<i>EP2365750</i>	<i>Benzoxazole kinase inhibitors and methods of use</i>

Annex 1 to Patent Assignment Agreement - Assigned Patents

Sweden	09823947.8	EP2365750		Benzoxazole kinase inhibitors and methods of use
Slovenia	09823947.8	EP2365750		Benzoxazole kinase inhibitors and methods of use
Slovakia	09823947.8	EP2365750		Benzoxazole kinase inhibitors and methods of use
San Marino	09823947.8	EP2365750	Expired	Benzoxazole kinase inhibitors and methods of use
European Patent	16171888.7	EP3153023	Granted	Benzoxazole kinase inhibitors and methods of use
Convention				
Switzerland	16171888.7	EP3153023		Benzoxazole kinase inhibitors and methods of use
Germany	16171888.7	EP3153023		Benzoxazole kinase inhibitors and methods of use
France	16171888.7	EP3153023		Benzoxazole kinase inhibitors and methods of use
United Kingdom	16171888.7	EP3153023		Benzoxazole kinase inhibitors and methods of use
Ireland	16171888.7	EP3153023		Benzoxazole kinase inhibitors and methods of use
Luxembourg	16171888.7	EP3153023		Benzoxazole kinase inhibitors and methods of use
Monaco	16171888.7	EP3153023		Benzoxazole kinase inhibitors and methods of use
Hong Kong	17110092.7	HK1236070	Granted	Benzoxazole kinase inhibitors and methods of use
Hong Kong	12102655.8	HK1162855	Granted	Benzoxazole kinase inhibitors and methods of use
India	3841/DELNP/2011	IN294963	Granted	Benzoxazole kinase inhibitors and methods of use
Indonesia	W00201101953	IDP000037626	Granted	Benzoxazole kinase inhibitors and methods of use
Indonesia	P-00201405032	IDP000057232	Granted	Benzoxazole kinase inhibitors and methods of use
Israel	212586	IL212586	Granted	Benzoxazole kinase inhibitors and methods of use
Israel	233677	IL233677	Granted	Benzoxazole kinase inhibitors and methods of use
Israel	240771		Abandoned	Benzoxazole kinase inhibitors and methods of use
Japan	2011-534529	JP5897333	Granted	Benzoxazole kinase inhibitors and methods of use
Japan	2014-179810	JP5897667	Granted	Benzoxazole kinase inhibitors and methods of use
Japan	2016-039988	JP6235058	Granted	Benzoxazole kinase inhibitors and methods of use
Japan	2017-205797		Abandoned	Benzoxazole kinase inhibitors and methods of use
Japan	2019-109399		Abandoned	Benzoxazole kinase inhibitors and methods of use
Japan	2020-173377		Abandoned	Benzoxazole kinase inhibitors and methods of use
Japan	2022-139129		Pending	Benzoxazole kinase inhibitors and methods of use
Korea, Republic of	10-2014-7030732	KR10-1737192	Granted	Benzoxazole kinase inhibitors and methods of use
Korea, Republic of	10-2011-7012657	KR10-1690339	Granted	Benzoxazole kinase inhibitors and methods of use
Malaysia	PI2011001927	MY166032A	Granted	Benzoxazole kinase inhibitors and methods of use
Malaysia	PI2015001118	MY182533A	Granted	Benzoxazole kinase inhibitors and methods of use

Annex I to Patent Assignment Agreement - Assigned Patents

Mexico	MX/a/2011/004523	MX320742	Granted	Benzoxazole kinase inhibitors and methods of use
Mexico	MX/a/2014/006582	MX341591	Granted	Benzoxazole kinase inhibitors and methods of use
Mexico	MX/a/2016/011082	MX361811	Granted	Benzoxazole kinase inhibitors and methods of use
New Zealand	592608	NZ592608	Granted	Benzoxazole kinase inhibitors and methods of use
New Zealand	609221	NZ609221	Granted	Benzoxazole kinase inhibitors and methods of use
Singapore	2011030525		Abandoned	Benzoxazole kinase inhibitors and methods of use
Singapore	10201501702W	SG10201501702W	Granted	Benzoxazole kinase inhibitors and methods of use
Singapore	10201501703T		Abandoned	Benzoxazole kinase inhibitors and methods of use
South Africa	2011/03270	2011/03270	Granted	Benzoxazole kinase inhibitors and methods of use
South Africa	2015/05582	2015/05582	Granted	Benzoxazole kinase inhibitors and methods of use
Turkey	2016/12030	2016-GE-346959	Granted	Benzoxazole kinase inhibitors and methods of use

CO/0228 family 3

Australia	2012294202	AU2012294202	Granted	Kinase inhibitor polymorphs
Algeria	140119	10371	Granted	Kinase inhibitor polymorphs
Brazil	BR112014003214A		Abandoned	Kinase inhibitor polymorphs
Belarus	a20140151			Kinase inhibitor polymorphs
Canada	CA2844742A		Abandoned	Kinase inhibitor polymorphs
Chile	CL2014000343A			Kinase inhibitor polymorphs
China	CN201280043863A		Abandoned	Kinase inhibitor polymorphs
Colombia	CO6960542A2			Kinase inhibitor polymorphs
Costa Rica	CR20140082A			Kinase inhibitor polymorphs
Dominican Republic	DOP2014000027A			Kinase inhibitor polymorphs
Eurasian Patent Convention	201490446	EA027970B1	Abandoned	Kinase inhibitor polymorphs
Armenia	201490446	027970		Kinase inhibitor polymorphs
Azerbaijan	201490446	027970		Kinase inhibitor polymorphs
Belarus	201490446	027970		Kinase inhibitor polymorphs
Kazakhstan	201490446	027970		Kinase inhibitor polymorphs
Kyrgyzstan	201490446	027970		Kinase inhibitor polymorphs
Moldova	201490446	027970		Kinase inhibitor polymorphs
Russia	201490446	027970		Kinase inhibitor polymorphs

Annex 1 to Patent Assignment Agreement - Assigned Patents

Tajikistan	201490446	027970	Kinase inhibitor polymorphs
Turkmenistan	201490446	027970	Kinase inhibitor polymorphs
Ecuador	SP-14-13236		Kinase inhibitor polymorphs
Egypt	PCT178/2014		Kinase inhibitor polymorphs
European patent convention	128217908		Kinase inhibitor polymorphs
Georgia	AP2012013414		Kinase inhibitor polymorphs
Hong Kong	14112711.7		Kinase inhibitor polymorphs
Hong Kong	15101873.3		Kinase inhibitor polymorphs
Indonesia	P-00201401372		Kinase inhibitor polymorphs
Israel	230850		Kinase inhibitor polymorphs
India	1147/DELNP/2014		Kinase inhibitor polymorphs
Indonesia	P00201401372	IDP000069454	Kinase inhibitor polymorphs
Japan	2014-525168	2014-521726	Kinase inhibitor polymorphs
Kenya	KE/P/2014/002000		Kinase inhibitor polymorphs
Kazakhstan	2014/1530.1	31273	Kinase inhibitor polymorphs
Mexico	MX/a/2014/001662		Kinase inhibitor polymorphs
Malaysia	PI 2014000363	MY-186267-A	Kinase inhibitor polymorphs
Morocco	36803		Kinase inhibitor polymorphs
New Zealand	622208	622208	Kinase inhibitor polymorphs
Patent Cooperation Treaty	PCT/US2012/050453		Kinase inhibitor polymorphs
Philippines ⁹	1-2014-500331	1-2014-500331	Kinase inhibitor polymorphs
Nigeria	NG/PT/C/2014/188	4161	Kinase inhibitor polymorphs
New Zealand	622208	622208	Kinase inhibitor polymorphs
Peru	PE2014000191A	PE20141358A1	Kinase inhibitor polymorphs
Thailand	1401000726		Kinase inhibitor polymorphs
Tunisia	TN2014/0063	23801	Kinase inhibitor polymorphs
Ukraine	a201402351		Kinase inhibitor polymorphs
Russia	2014109023	263588	Kinase inhibitor polymorphs
Singapore	10201606288T		Kinase inhibitor polymorphs
Singapore	2014009492		Kinase inhibitor polymorphs
South Korea	10-2014-7006105		Kinase inhibitor polymorphs
South Africa	2014/01211	2014/01211	Kinase inhibitor polymorphs

Annex 1 to Patent Assignment Agreement - Assigned Patents

South Africa	2015/02063			Kinase inhibitor polymorphs
United States of America	61/522624	Expired		Kinase inhibitor polymorphs
United States of America	14/238426	Abandoned		Kinase inhibitor polymorphs
United States of America	15/481582	Abandoned		Kinase inhibitor polymorphs
Uzbekistan				
Vietnam	1-2014-00758	20269	Granted	Kinase inhibitor polymorphs
COM-228 Family †				
United States of America	14/360267	9174994	Granted	Enhanced treatment regimens using mTOR inhibitors
United States of America	14/884120	9669032	Granted	Enhanced treatment regimens using mTOR inhibitors
United States of America	13/683967		Abandoned	Enhanced treatment regimens using mTOR inhibitors
Patent Cooperation Treaty	PCT/US12/66431		Nationalized	Enhanced treatment regimens using mTOR inhibitors
Japan	2014-543592	6130391	Granted	Enhanced treatment regimens using mTOR inhibitors
United States of America	61/563516		Expired	Enhanced treatment regimens using mTOR inhibitors
Canada	2856803		Abandoned	Enhanced treatment regimens using mTOR inhibitors
China	201280067718.1		Abandoned	Enhanced treatment regimens using mTOR inhibitors
European Patent Convention	12851154		Abandoned	Enhanced treatment regimens using mTOR inhibitors
Hong Kong	15103955		Abandoned	Enhanced treatment regimens using mTOR inhibitors
COM-228 Family ‡				
Japan [§]	2014-509505	6047149	Granted	Combination pharmaceutical compositions and uses thereof
Canada [*]	2836769	2836769	Granted	Combination pharmaceutical compositions and uses thereof
China [*]	201280033418.1	CN103703174B	Granted	Combination pharmaceutical compositions and uses thereof
Europe [*]	12779459.2	EP2705181	Granted	Combination pharmaceutical compositions and uses thereof
	Switzerland	12779459.2	EP2705181	Combination pharmaceutical compositions and uses thereof
	Germany	12779459.2	EP2705181	Combination pharmaceutical compositions and uses thereof
	Spain	12779459.2	EP2705181	Combination pharmaceutical compositions and uses thereof
	France	12779459.2	EP2705181	Combination pharmaceutical compositions and uses thereof
	United Kingdom	12779459.2	EP2705181	Combination pharmaceutical compositions and uses thereof
	Luxembourg	12779459.2	EP2705181	Combination pharmaceutical compositions and uses thereof
	Monaco	12779459.2	EP2705181	Combination pharmaceutical compositions and uses thereof

Annex 1 to Patent Assignment Agreement - Assigned Patents

<i>Ireland</i>	12779459.2	EP2705181	<i>Abandoned</i>	<i>Combination pharmaceutical compositions and uses thereof</i>
<i>Italy</i>	12779459.2	EP2705181		<i>Combination pharmaceutical compositions and uses thereof</i>
Hong Kong *	14109188.7	1195793	Granted	Combination pharmaceutical compositions and uses thereof
Macao *	J/002673	J/002673	Granted	Combination pharmaceutical compositions and uses thereof
United States of America	61/482568		Abandoned	Combination pharmaceutical compositions and uses thereof
Patent Cooperation Treaty	PCT/US2012/036688		Nationalized	Combination pharmaceutical compositions and uses thereof
United States of America	15/092713	US10172858	Abandoned	Combination pharmaceutical compositions and uses thereof
United States of America	14/113982		Abandoned	Combination pharmaceutical compositions and uses thereof

PATENT

REEL: 064156 FRAME: 0756

RECORDED: 07/05/2023